Prostate Cancer

Foundation Medicine wins FDA approval for companion diagnostic to prostate cancer treatment

FoundationOne CDx analyzes more than 300 cancer-related genes for genomic alterations. The ability of the product to test for alterations and select gene rearrangements and genomic signatures has led to its approval as a CDx for multiple products.

August 16, 2023

Veracyte raises full-year outlook on prostate cancer growth, reveals executive is leaving

In the second quarter, Veracyte reported sales of 15,000 Decipher Prostate tests. The 50% year-over-year increase in test volumes helped the company to report total sales of $90.3 million.

August 11, 2023

Quest Diagnostics teams up with Envision Science on prostate cancer biomarkers

The test aims to improve the accuracy of grading biopsies for prostate cancer, which is one of the most prevalent and deadly cancers affecting men.

July 27, 2023

Quest launches biomarker test to improve grading of prostate cancer biopsies

Building on the Australian research and working with Envision Sciences, the Australian diagnostics company that owns the biomarker intellectual property, Quest’s subspecialty pathology business, AmeriPath, has developed a tissue-based test.

July 17, 2023

At ASCO meeting, Veracyte highlights prostate cancer study data using genomics database

The Decipher GRID database, which is used by Veracyte and its partners in urologic cancer research, comprises more than 100,000 whole-transcriptome profiles from patients with urologic cancers.

May 30, 2023

Some prostate cancer policies drive overdiagnosis, argue experts

Prostate cancer test-by-request policies have led to excessive PSA testing for asymptomatic men, overdiagnosis, overtreatment, and inequity, contend experts.

May 18, 2023

EU project aims to reduce prostate cancer via early detection

A new three-year EU project aims to reduce prostate cancer mortality through smart early detection, while avoiding overdiagnosis and overtreatment.

April 25, 2023

MDxHealth nabs reimbursement for prostate cancer risk test

The firm's Select mdx test will now be reimbursed in the U.S. for Medicare patients who meet coverage conditions under a specific, foundational Local Coverage Determination (LCD).

April 20, 2023

Veracyte announces data for prostate cancer classifier in micrometastatic disease

The published data show that the Decipher Prostate scores for patients with high-risk and very high-risk disease were highly correlated with the upstaging predictions by a clinically-validated algorithm.

April 17, 2023

Older males may be overscreened for prostate cancer

Researchers have found that older males were often overscreened for prostate cancer, despite national guidelines outlining the limited value of such screening.

April 11, 2023

Racial groups negatively impacted by exclusion from cancer research

Researchers are calling for greater inclusion of people with African ancestry in genomic research to improve prostate cancer outcome disparities.

March 10, 2023

Active surveillance on the rise for low-risk prostate cancer

A large study indicates that active surveillance rates for management of low-risk prostate cancer are rising nationally, but are still not optimal.

March 2, 2023

Page 1 of 7

Next Page